Clinical Trial Update: MicroPhage S. Aureus / MSSA / MRSA Blood Culture Beta Trial

View source ↗

Summary

A completed beta trial by MicroPhage, Inc. evaluating phage therapy against Staphylococcus aureus bacteremia (MSSA/MRSA) using blood culture endpoints.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacteremia
• Sepsis
• Staphylococcus Aureus Infection

Drugs mentioned

• MicroPhage

Snippet

Sponsor: MicroPhage, Inc. | Conditions: Bacteremia, Staphylococcal Infection | Status: COMPLETED